The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Metabolism as a New Avenue for Hepatocellular Carcinoma Therapy
Int J Mol Sci. 2023 Feb 13;24(4):3710. doi: 10.3390/ijms24043710.
1Interdisciplinary Department of Medicine, School of Medicine, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy.
2Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Abstract
Hepatocellular carcinoma is today the sixth leading cause of cancer-related death worldwide, despite the decreased incidence of chronic hepatitis infections. This is due to the increased diffusion of metabolic diseases such as the metabolic syndrome, diabetes, obesity, and nonalcoholic steatohepatitis (NASH). The current protein kinase inhibitor therapies in HCC are very aggressive and not curative. From this perspective, a shift in strategy toward metabolic therapies may represent a promising option. Here, we review current knowledge on metabolic dysregulation in HCC and therapeutic approaches targeting metabolic pathways. We also propose a multi-target metabolic approach as a possible new option in HCC pharmacology.